SHERIDAN, WYOMING – NOVEMBER 06, 2024-Roche, a global pioneer in pharmaceuticals and diagnostics, is set to present groundbreaking data from its extensive hematology portfolio at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition. The data, encompassing nine blood disorders, will be showcased in over 40 abstracts, underscoring Roche's unwavering dedication to improving patient outcomes. [cite: 1, 2]
The company's commitment to innovation is evident in the diverse range of presentations, including long-term follow-up data for approved medicines like Polivy® (polatuzumab vedotin), Lunsumio® (mosunetuzumab), and Columvi® (glofitamab), as well as novel investigational combination data. [cite: 2, 3, 4]
A key highlight is the five-year data from the Phase III POLARIX study, which demonstrates the potential of Polivy in combination with MabThera®/Rituxan® (rituximab), cyclophosphamide, doxorubicin, and prednisone (R-CHP) to deliver durable remissions and enhance overall survival (OS) for patients with previously untreated diffuse large B-cell lymphoma (DLBCL). This breakthrough signifies notable progress in a therapeutic area that has seen limited advancements in recent decades.
Further bolstering Roche's commitment to advancing hematologic care, extended follow-up data from pivotal studies of Lunsumio and Columvi reveal long-lasting remissions and immune system recovery post-treatment. These findings support the use of fixed-duration bispecific antibodies for follicular lymphoma (FL) and DLBCL, respectively. [cite: 4, 5]
In a significant step towards improving patient experience, Roche will present data for a subcutaneous formulation of Lunsumio, demonstrating high response rates and a favorable safety profile. This innovative approach could streamline administration and enhance convenience for patients with relapsed or refractory follicular lymphoma (FL). [cite: 5, 6]
Moreover, new patient-reported outcomes data from the Phase III STARGLO study indicate comparable health-related quality of life between treatment arms, despite variations in the number of cycles received. This underscores the potential benefits of Columvi-based therapies for patients with DLBCL. [cite: 6, 7]
"Our scientific expertise, combined with the breadth of our portfolio and pipeline, also provides a unique opportunity to develop combination regimens that aim to improve the lives of patients even further," said a Roche spokesperson. [cite: 27]
Roche's presence at ASH 2024 is a testament to its ongoing efforts to revolutionize the treatment of blood disorders. The company's dedication to research and development, coupled with its patient-centric approach, is driving progress across a spectrum of hematologic diseases, offering renewed hope for patients and healthcare providers alike. [cite: 22, 23, 24, 25, 26, 27]
**About Roche**
Established in 1896, Roche has grown into a global leader in biotechnology and in-vitro diagnostics. The company's pursuit of scientific excellence has led to the development of groundbreaking medicines and diagnostics, improving and saving lives worldwide. Roche's commitment to personalized healthcare and sustainable practices further solidifies its position as a frontrunner in the healthcare industry. [cite: 28, 29, 30, 31, 32, 33, 34, 35]
**About Roche in Hematology**
With over 25 years of experience in developing medicines for blood diseases, Roche possesses profound knowledge and expertise in this therapeutic area. The company continues to invest heavily in research and development, striving to bring innovative treatment options to patients with various hematologic conditions. Roche's approved medicines include MabThera®/Rituxan® (rituximab), Gazyva®/Gazyvaro® (obinutuzumab), Polivy® (polatuzumab vedotin), Venclexta®/Venclyxto® (venetoclax) in collaboration with AbbVie, Hemlibra® (emicizumab), PiaSky® (crovalimab), Lunsumio® (mosunetuzumab), and Columvi® (glofitamab). [cite: 22, 23, 24]
Among the key presentations at ASH 2024:
* Five-year analysis of the POLARIX study, showcasing the long-term benefits of Polivy in combination with R-CHP for DLBCL.
* Extended follow-up data from the GO29781 and NP30179 studies, supporting the use of fixed-duration Lunsumio and Columvi for FL and DLBCL, respectively. [cite: 4, 5, 9, 10, 11, 12]
* First presentation of data for a subcutaneous formulation of Lunsumio, highlighting its potential to improve patient experience. [cite: 5, 6, 13, 14, 15]
* New patient-reported outcomes data from the STARGLO study, indicating comparable health-related quality of life between treatment arms. [cite: 6, 7, 16]
* Investigational study combinations of Polivy with Lunsumio and Columvi in relapsed or refractory DLBCL, further expanding the potential of these novel therapies. [cite: 7, 8, 17, 18, 19]
Roche's participation in ASH 2024 signifies its unwavering